Want to see CCCC full AI Analyst Report?
CCCC Stock Chart & Stats
$3.40
-$0.25(-6.85%)
At close: 4:00 PM EDT
$3.40
-$0.25(-6.85%)
Day’s Range― - ―
52-Week Range$1.69 - $5.17
Previous CloseN/A
Volume2.58M
Average Volume (3M)3.60M
Market Cap
$412.42M
Enterprise Value$154.35
Total Cash (Recent Filing)$253.66M
Total Debt (Recent Filing)$56.86M
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Oct 29, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding110,567,220
10 Day Avg. Volume2,926,881
30 Day Avg. Volume3,597,566
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside150.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$23.18M
Bulls Say, Bears Say
Bulls Say
Proprietary TORPEDO Degrader PlatformC4’s TORPEDO platform is a durable, proprietary scientific asset that enables creation of small-molecule degraders across targets. Platform ownership supports repeated program generation, strengthens partnership appeal, and underpins a multi-product pipeline rather than a single-drug dependency.
Validated Strategic CollaborationsA collaboration with a major pharma like Roche provides both non-dilutive capital and external validation of modality and technology. Such partnerships spread development risk, can accelerate novel modality applications, and open commercialization pathways beyond internal resources.
Funded Clinical Runway To End-2028A reported cash balance and runway into 2028 materially reduces near-term fundraising pressure, allowing C4 to advance multiple clinical programs and de-risk technical milestones over the medium term, increasing the chance of value-inflecting data before new financing is required.
Bears Say
High Cash BurnSustained negative operating and free cash flow at this scale raises persistent financing dependence. Even with current cash, continued burn can force dilutive financings or constrained R&D choices, making long-term program funding and strategic optionality contingent on future capital access.
Declining Revenue And Persistent LossesA shrinking revenue base alongside deeply negative margins shows the business is not yet generating sustainable commercial income. Persistent losses erode returns and equity over time, increasing pressure to demonstrate clinical or partnership milestones to restore positive operating dynamics.
Revenue Dependent On Collaborations/milestonesReliance on upfronts, milestones, reimbursements, and future royalties creates lumpy, partner-dependent cash flows. This model reduces revenue predictability and ties commercial outcomes to external development timelines and partner decisions rather than recurring product-derived revenues.
C4 Therapeutics News
CCCC FAQ
What was C4 Therapeutics, Inc.’s price range in the past 12 months?
C4 Therapeutics, Inc. lowest stock price was $1.69 and its highest was $5.17 in the past 12 months.
What is C4 Therapeutics, Inc.’s market cap?
C4 Therapeutics, Inc.’s market cap is $412.42M.
When is C4 Therapeutics, Inc.’s upcoming earnings report date?
C4 Therapeutics, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 78 days.
How were C4 Therapeutics, Inc.’s earnings last quarter?
C4 Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.226 by $0.046.
Is C4 Therapeutics, Inc. overvalued?
According to Wall Street analysts C4 Therapeutics, Inc.’s price is currently Undervalued.
Does C4 Therapeutics, Inc. pay dividends?
C4 Therapeutics, Inc. does not currently pay dividends.
What is C4 Therapeutics, Inc.’s EPS estimate?
C4 Therapeutics, Inc.’s EPS estimate is -0.23.
How many shares outstanding does C4 Therapeutics, Inc. have?
C4 Therapeutics, Inc. has 110,567,220 shares outstanding.
What happened to C4 Therapeutics, Inc.’s price movement after its last earnings report?
C4 Therapeutics, Inc. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.226. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of C4 Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CCCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
C4 Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (150.00% Upside)
$8.50 (150.00% Upside)
Blogger Sentiment
Bullish
CCCC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 306.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.92%
Trailing 12-Months
Company Description
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
CCCC Stock 12 Month Forecast
Average Price Target
$8.50
▲(150.00% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Seres Therapeutics
―
Eledon Pharmaceuticals
―
Tevogen Bio Holdings
―
Actuate Therapeutics, Inc.
―
Ownership Overview
2.97% Insiders
8.63% Mutual Funds
4.65% Other Institutional Investors
71.79% Public Companies and
Individual Investors